Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes

Table 3

Disseminated/Localized Zoster in relation to SLE treatment.

SLE Therapy	Disseminated (𝑛=7)	Localized (𝑛=25)	𝑃 value
	𝑁 (%)	𝑁 (%)
MPSL	6 (85.7)	10 (40.0)	.0094^∗
Cyclo IV	6 (85.7)	8 (32.0)	.0024^∗
AZA	5 (71.4)	9 (36.0)	.0808^∗
MMF	6 (85.7)	0.0 (0.0)	.0000^∗

∗significant (𝑃<.05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, AZA: azathioprine, MMF: mycophenolate mofetil.